Where Discovery Meets Collaboration. A platform dedicated to advancing liver & cardiometabolic health through education, research, and global dialogue. Stay tuned for details on our inaugural meeting in 2026.

New @EASLnews guidelines on vascular liver diseases: from PVT to Budd–Chiari, PSVD, SOS, splanchnic aneurysms & hepatic AV fistulas. Updated info with evidence-graded, personalised recommendations and a clear push for multidisciplinary care @EASLedu https://t.co/Uu9mOiUJn1

True eradication of Hepatitis C will ultimately require an effective vaccine @HEP_Journal study showed conserved genotype 1–6 antigens & sequential 1a→3a immunogens generated broad, cross-reactive T-cell responses Important steps toward a HCV vaccine https://t.co/wFz9tVXsDC

Quarterback mentality on full display — 15 hours post-transplant and already lifting others up through organ-donation advocacy. Elite resilience. Proud to share your message. Best of luck in your recovery! 💪 💪 💚 #DonateLife

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study - @TheLancet #livertwitter

Original Article Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study Moeckli et al. #LiverX https://t.co/CRO0CFqLHP

Novel MR biomarkers in MASH Multiparametric MRI (cT1, PDFF) correlated well with histologic response in MAESTRO-NASH Phase 3 trial of resmetirom Strengthens case for MR-based biomarkers as emerging tools for treatment response in MASH, both in trials & evolving clinical care

Wonderful case discussion on the intersection of obesity, AUD, and bariatric surgery by @BrighamWomens GI/Hepatology fellow @brittybb @AASLDtweets #TLM25

Excited to discuss integrating MASLD, obesity, and AUD management in real-world hepatology practice. #TLM25

Great work from the Danish 🇩🇰 group — PEth predicts short-term hepatic decompensation independently of liver fibrosis markers, though its prognostic power fades over time. Important insights for how we interpret alcohol biomarkers clinically. #AASLD2025 #TLM2025

🧬The quest goes on for effective PSC therapy Phase 3 PRIMIS trial: FXR agonist cilofexor showed no antifibrotic benefit vs placebo at 96 weeks (fibrosis progression 31% vs 33%). Pruritus: 49% vs 36%; no new safety signals. #PSC #ClinicalTrials #LiverX https://t.co/FyuGxPni5D

RASP-modulating therapy targets reactive aldehyde species—toxic lipid-derived molecules that drive oxidative stress and inflammation. By neutralizing these RASPs, it aims to reduce tissue injury and immune activation across inflammatory diseases, including liver injury.

Aldeyra reports positive Phase 2 proof-of-concept data in alcohol-associated hepatitis with RASP-modulating therapy—but won’t pursue AH, shifting focus to next-gen anti-inflammatory programs Encouraging signal, yet underscores the ongoing vacuum of industry commitment in AH

Serum bile acids within 1 yr post Kasai strongly predicted portal HTN & high-risk varices within 5 yrs (AUC 0.89–0.93) Early sBA monitoring may identify biliary atresia patients at risk for progressive portal complications despite good bilirubin clearance https://t.co/WGedlDu3j1

Glycine supplementation in severe obesity (100 mg/kg × 2 wks) ➜ ↑plasma glycine, improved 1-C metabolites and ↓triglycerides/aminotransferases — improved the glycine-serine-glutamate index Proof-of-concept for MASLD? @NaturePortfolio @SciReports https://t.co/2WiBMG01GV

Dynamic weight trajectories best predict MASLD prognosis @HEP_Journal @AASLDtweets 📉 >5% loss→ improved liver stiffness 📈 >5% gain→ ↑ risk of liver events (aHR 1.84) & stiffness progression Obesity reversal restores outcomes similar to non-obese https://t.co/S3P0l9yLJs

Lilly’s oral GLP-1 agonist orforglipron met both primary endpoints in Phase 3 trials (ACHIEVE-2 & ACHIEVE-5) A1C ↓ by up to 1.7 % vs 0.8% dapagliflozin; 2.1 % with basal insulin — plus weight & cardio benefits Strong oral contender for foundational T2D therapy #Diabetes #GLP1

Rivus Pharma oral metabolic accelerator HU6 reduced liver fat & improved adiposity markers in adults with MASH (Phase 2 M-ACCEL) Late-breaker @AASLDtweets #TLM2026 An oral therapy that improves both hepatic and systemic metabolism #MASH #MASLD #MetabolicHealth #Obesity

Early MELD 3.0 narrowed sex gaps in liver transplant access, but benefit faded—HEIGHT remains a key mediator @AASLDtweets @HEP_Journal Body size has always influenced allocation, is it time to refine how we account for it? #LiverX #LiverTransplant 🔗

1st successful genetically engineered pig-to-human auxiliary liver xenotransplantation @JHepatology 10-gene edited pig liver sustained human function for 38 days (limited by thrombotic microangiopathy)—demonstrating feasibility as a bridge-to-transplant https://t.co/sZiw5ZMTZs

Novo Nordisk to acquire Akero Therapeutics, adding the FGF21 analog efruxifermin to its metabolic & liver-disease pipeline — underscoring growing industry confidence in FGF21-based therapies for MASH after Phase 2b data showed fibrosis improvement in F2/F3. Phase 3 on the horizon